Skip to product information
1 of 1
Regular price £105.65 GBP
Regular price £159.00 GBP Sale price £105.65 GBP
Sale Sold out
Free UK Shipping

Freshly Printed - allow 10 days lead

Patently Innovative
How Pharmaceutical Firms Use Emerging Patent Law to Extend Monopolies on Blockbuster Drugs

R A Bouchard (Author)

9781907568121, Elsevier Science

Hardback, published 2 January 2012

296 pages
23.3 x 15.6 x 2.3 cm, 0.78 kg

Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products.

Dedication

Acknowledgements

List of figures and tables

List of abbreviations

About the author

Chapter 1: Introduction

Abstract:

1.1 The emergence of global pharmaceutical linkage

1.2 Canadian pharmaceutical linkage regulations

1.3 Organization

Chapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy

Abstract:

2.1 Drug approval

2.2 Patents

2.3 Linkage regulations

2.4 IPR rights and innovation policy

Chapter 3: Empirical analysis of drug approval

Abstract:

3.1 Introduction

3.2 Analysis

3.3 Results

3.4 Discussion

3.5 Interpretation of data

3.6 Study limitations

3.7 Assessing the lifecycle approach: the long view

3.8 Government as representative public agent

3.9 Summary and conclusions

Chapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage

Abstract:

4.1 Introduction

4.2 Methods

4.3 Results

4.4 Discussion

Chapter 5: Empirical analysis of drug patenting in multiple high-value cohorts

Abstract:

5.1 Introduction

5.2 Methods

5.3 Results

5.4 Discussion

5.5 Summary and conclusions

Chapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success?

Abstract:

6.1 Introduction

6.2 Debate preceding Bill C-91

6.3 ‘Original policy intent’

6.4 ‘Patent-specific’ analysis

6.5 Statutory interpretation

6.6 Revisiting the empirical data

6.7 Summary and conclusions

Chapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage

Abstract:

7.1 Hypotheses regarding cluster-based drug development

7.2 Globalization of pharmaceutical linkage

Index

Subject Areas: Pharmacology [MMG], Intellectual property law [LNR]

View full details